Chronic kidney disease (CKD) is becoming a major public health issue around the world. The discovery of a specific collection of early biomarkers for CKD is critical for furthering disease understanding, enhancing diagnosis, treatment, or development, and monitoring drug efficacy. Because kidney fibrosis is a common pathophysiological pathway to end-stage renal failure, regardless of the initial renal insult, these biomarkers are considered early tubulo-interstitial fibrosis biomarkers. The availability of a specialised collection of biomarkers for CKD is a requirement for developing and validating new devoted medications in clinics without having to wait years for a functional response in patients.
